Syndax Pharmaceuticals, Inc. (SNDX)
SNDX Stock Price Chart
Explore Syndax Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SNDX price movements and trends.
SNDX Company Profile
Discover essential business fundamentals and corporate details for Syndax Pharmaceuticals, Inc. (SNDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Mar 2016
Employees
270.00
Website
https://www.syndax.comCEO
Michael A. Metzger
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
SNDX Financial Timeline
Browse a chronological timeline of Syndax Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 2 Mar 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$0.74, while revenue estimate is $48.57M.
Earnings released on 4 Aug 2025
EPS came in at -$0.83 surpassing the estimated -$1.00 by +17.00%, while revenue for the quarter reached $37.96M , missing expectations by -16.85%.
Earnings released on 5 May 2025
EPS came in at -$0.98 surpassing the estimated -$1.04 by +5.77%, while revenue for the quarter reached $20.04M , beating expectations by +8.06%.
Earnings released on 3 Mar 2025
EPS came in at -$1.10 falling short of the estimated -$1.08 by -1.85%, while revenue for the quarter reached $7.68M , missing expectations by -39.93%.
Earnings released on 5 Nov 2024
EPS came in at -$0.98 surpassing the estimated -$1.13 by +13.27%, while revenue for the quarter reached $12.50M , missing expectations by -89.15%.
Earnings released on 1 Aug 2024
EPS came in at -$0.80 surpassing the estimated -$0.91 by +12.09%, while revenue for the quarter reached $3.50M .
Earnings released on 8 May 2024
EPS came in at -$0.85 surpassing the estimated -$0.96 by +11.46%.
Earnings released on 27 Feb 2024
EPS came in at -$1.00 falling short of the estimated -$0.99 by -1.01%, while revenue for the quarter reached $536.00K .
Earnings released on 2 Nov 2023
EPS came in at -$0.73 surpassing the estimated -$0.80 by +8.75%.
Earnings released on 3 Aug 2023
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%.
Earnings released on 8 May 2023
EPS came in at -$0.59 surpassing the estimated -$0.61 by +3.28%.
Earnings released on 28 Feb 2023
EPS came in at -$0.62 surpassing the estimated -$0.64 by +3.13%.
Earnings released on 3 Nov 2022
EPS came in at -$0.58 surpassing the estimated -$0.65 by +10.77%.
Earnings released on 8 Aug 2022
EPS came in at -$0.62 surpassing the estimated -$0.65 by +4.62%.
Earnings released on 9 May 2022
EPS came in at -$0.63 matching the estimated -$0.63.
Earnings released on 1 Mar 2022
EPS came in at $1.81 surpassing the estimated $0.28 by +546.43%, while revenue for the quarter reached $126.58M , beating expectations by +1.91K%.
Earnings released on 15 Nov 2021
EPS came in at -$0.40 surpassing the estimated -$0.64 by +37.50%, while revenue for the quarter reached $12.38M , beating expectations by +3.25%.
Earnings released on 9 Aug 2021
EPS came in at -$0.44 surpassing the estimated -$0.74 by +40.54%, while revenue for the quarter reached $379.00K , meeting expectations.
Earnings released on 11 May 2021
EPS came in at -$0.54 surpassing the estimated -$0.64 by +15.62%, while revenue for the quarter reached $379.00K , beating expectations by +72.27%.
Earnings released on 8 Mar 2021
EPS came in at -$0.44 falling short of the estimated -$0.43 by -2.33%, while revenue for the quarter reached $380.00K , beating expectations by +58.33%.
Earnings released on 2 Nov 2020
EPS came in at -$0.46 falling short of the estimated -$0.42 by -9.52%, while revenue for the quarter reached $379.00K , beating expectations by +4.27%.
SNDX Stock Performance
Access detailed SNDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.